Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 10/20 | 0.51 |
| ▸ | SLC2A2 | P11168 | 4/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12819176 | 0.91 | SLC2A1 (0.61) | SLC2A1SLC2A2KCNK3KCNK9 | |
| SCHEMBL15914942 | 0.86 | SLC2A1 (0.53) | SLC2A1SLC2A2KCNK3KCNK9 | |
| SCHEMBL15915224 | 0.84 | SLC2A2 (0.47) | SLC2A1SLC2A2KCNK3KCNK9PRNP | |
| SCHEMBL15914730 | 0.82 | SLC2A1 (0.44) | SLC2A1SLC2A2KCNK3KCNK9PRNP | |
| SCHEMBL12819125 | 0.79 | SLC2A1 (0.54) | SLC2A1SLC2A2KCNK3KCNK9 | |
| SCHEMBL12818980 | 0.79 | SLC2A1 (0.79) | SLC2A1SLC2A2 | |
| SCHEMBL15914692 | 0.79 | SLC2A1 (0.38) | SLC2A1SLC2A2KCNK3KCNK9PRNP | |
| SCHEMBL12819283 | 0.78 | SLC2A1 (0.64) | SLC2A1SLC2A2KCNK3KCNK9 | |
| SCHEMBL12818929 | 0.77 | SLC2A1 (0.63) | SLC2A1SLC2A2 | |
| SCHEMBL12819010 | 0.77 | SLC2A1 (0.51) | SLC2A1SLC2A2KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM TECHNOLOGY TRANSFER GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | HIF1A, HIF1AN, EGLN3 | SLC2A1 1235/4885SLC2A2 1610/4885KCNK3 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.